Paclitaxel as a first line chemotherapy agent in the treatment of ovarian cancer
Record ID 31998008874
At present in the UK, paclitaxel is licensed only for the treatment of platinum-resistant ovarian cancer and recurrent breast cancer. The licence for 1st line ovarian cancer is likely to be granted in 1996. This report considers the use of paclitaxel as a 1st line chemotherapeutic agent.
Authors' results and conclusions:
In the RCT which examined paclitaxel-cisplatin, out of the sample of 100, 51 patients showed a complete clinical response and 73 showed a complete or partial clinical response. This was more than in any of the other studies. Median survival was found to be 38 months, compared with results from the other studies of 20 months with single agent carboplatin and 24 months with CAP.
Paclitaxel-cisplatin appears to be the most effective, but also the least cost-effective, of the three agents. However the evidence on which this report is based is poor. The phase III RCTs currently being performed may provide substantial comparative evidence on paclitaxel, carboplatin and CAP as 1st line chemotherapy agents. For the moment, therefore, paclitaxel-cisplatin is recommended, along with other treatments CAP and carboplatin, but in view of the uncertainty of how it fits in with total treatments and the fact that trials are still underway it should be reviewed in 12-18 months.
English language abstract:
An English language summary is available
- Antineoplastic Agents
- Costs and Cost Analysis
- Ovarian Neoplasms
Wessex Institute for Health Research and Development
Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Wessex Institute for Health Research and Development (WIHRD)